Pallas Health vs BreezeMeds: Which GLP-1 Option Fits You
Pallas Health vs BreezeMeds compares two online clinician-reviewed weight-loss services. Quick verdict: Pallas Health emphasizes clinician choice between brand-name pens and US-compounded GLP-1 with a low intro price, while BreezeMeds highlights injectable and oral options with starting prices typically higher than Pallas’s compounded intro offer.
Start Pallas intake from $139 first month
How these providers differ at a glance
Both are online and clinician-reviewed, but the most distinctive differences are price structure and intro pricing, medication formats and brand versus compounded availability, clear renewal and billing details, and state or visit requirements. The sections below compare those points directly using only the supplied facts.
1. Pricing and renewal terms
Pallas Health documents compounded semaglutide at $139 for the first month then $597 every 12 weeks, a $199 per month average; compounded tirzepatide is $179 first month then $897 every 12 weeks ($299/mo average). Pallas also lists brand-name Wegovy, Ozempic, Zepbound and Mounjaro as cash-pay monthly prices (for example Wegovy $1,349). BreezeMeds shows semaglutide injection starting at $199/mo and tirzepatide injection starting at $299, with oral semaglutide and oral tirzepatide displayed from $399, and a separate $169 figure that is not clearly tied to a product.
See Pallas pricing and clinician options
2. Medication formats and choices
Pallas offers clinician selection between FDA-approved brand-name pens and compounded semaglutide or tirzepatide prepared in the USA when brand medication is not the right fit. BreezeMeds lists injectable semaglutide and tirzepatide and also oral semaglutide and oral tirzepatide. BreezeMeds notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.
3. Compounding and regulatory notes
Pallas states that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality, and that Pallas does not manufacture or compound medication; compounding is done by US-licensed pharmacies. BreezeMeds likewise indicates that compounding and FDA status require confirmation and that approval status must be confirmed for specific medications.
4. Delivery model, visit requirements and support
Pallas is 100 percent online with a US-licensed clinician review and is asynchronous in most states; a video visit is required in seven states plus Washington, D.C. Pallas includes provider care, ongoing check-ins and care-team messaging inside the plan price with no membership fee and offers free expedited shipping. BreezeMeds advertises online intake, personalized treatment plans and discreet home delivery, and urges patients to confirm eligibility, state availability, total cost and renewal terms before enrollment.
Quick comparison table
| Criteria | Pallas Health | BreezeMeds |
|---|---|---|
| Intro pricing cited | Compounded semaglutide $139 first month | Semaglutide injection starting at $199; $169 figure unclear |
| Ongoing price details | $597 per 12 weeks for compounded semaglutide ($199/mo avg) | Starting prices shown; renewal terms not fully visible |
| Brand vs compounded | Offers FDA-approved brand pens or US-compounded products | Injectable and oral options; approval status must be confirmed |
| Formats available | Brand-name pens and compounded injections (semaglutide, tirzepatide) | Injectable semaglutide and tirzepatide; oral semaglutide and tirzepatide |
| Shipping and access | 100% online, free expedited shipping, asynchronous in most states | Discreet home delivery; availability subject to live offer and state rules |
5. Billing, insurance and fees
Pallas is cash-pay only and does not bill insurance; FSA or HSA use may require a Letter of Medical Necessity. BreezeMeds materials ask users to confirm costs and whether insurance is accepted, but detailed billing commitments were not fully visible in the captured evidence.
Check BreezeMeds starting options
How to choose between Pallas Health and BreezeMeds
Use the primary keyword when deciding: Pallas Health vs BreezeMeds shows clear contrasts. If the lowest documented introductory compounded price is a priority and you want clinician choice between brand-name pens and US-compounded products, Pallas makes that explicit with a $139 first-month compounded semaglutide plan and clinician-led selection. If you need or prefer oral GLP-1 options or want to review multiple injection and oral formats up front, BreezeMeds displays injectable and oral options and lists starting prices for those formats, though you should confirm approval status, state availability and renewal terms.
Compare Pallas medication options now
Review BreezeMeds intake and availability
Choose Pallas Health if…
you want a clinician to decide between FDA-approved brand pens or a US-compounded semaglutide or tirzepatide option, prefer a documented $139 first-month compounded semaglutide offer with plan care and free expedited shipping, and accept cash-pay billing with plan prices that include provider care and messaging.
Choose BreezeMeds if…
you want visible injectable and oral GLP-1 formats up front and will confirm specific product approval, state availability and renewal terms before enrolling because BreezeMeds lists starting prices for injectables and oral options but asks users to verify details on the live offer.
Primary keyword reference: Pallas Health vs BreezeMeds.